The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia

Published:2020-12-19 Issue:3 Volume:10 Page:797-805
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Altman Jessica K.¹,Perl Alexander E.²,Hill Jason E.³,Rosales Matt³,Bahceci Erkut³,Levis Mark J.⁴

Affiliation:

1. Robert H Lurie Comprehensive Cancer Center Northwestern University Chicago IL USA

2. Abramson Comprehensive Cancer Center University of Pennsylvania Philadelphia PA USA

3. Astellas Pharma US, Inc. Northbrook IL USA

4. Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore MD USA

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3652

Reference28 articles.

1. Evaluating measurable residual disease in acute myeloid leukemia

2. Molecular Minimal Residual Disease in Acute Myeloid Leukemia

3. Minimal residual disease in acute myelogenous leukemia

4. Methods of Detection of Measurable Residual Disease in AML

5. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clonal Dynamics and Relapse Risk Revealed by High-Sensitivity FLT3-Internal Tandem Duplication Detection in Acute Myeloid Leukemia;Modern Pathology;2024-09

2. Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia;Blood;2024-07-11

3. Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication;International Journal of Molecular Sciences;2023-03-01

4. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia;Journal of Clinical Oncology;2022-12-10

5. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome;Blood;2022-12-01